JSJeffrey A. Switzer

Jeffrey A. Switzer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jeffrey A. Switzer has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 December 2013
      • Vol. 19  (12) , 976-85

    Cost utility of hub-and-spoke telestroke networks from societal perspective.

    by Bart M Demaerschalk, Jeffrey A Switzer, Jipan Xie, Liangyi Fan, Kathleen F Villa, Eric Q Wu

    A hub-and-spoke telestroke network is an effective way to extend quality emergency stroke care to remote hospitals and improve patient outcomes. To evaluate the cost utility of a telestroke network in the management of acute ischemic stroke from the societal perspective. A lifetime Markov model was developed to compare the incremental costs and effectiveness of a telestroke network. One-year transition probabilities between the 3 health states based on the modified Rankin scale--minimal-to-no disability, moderate-to-severe disability, and death--were derived from literature. Costs included telemedicine setup and maintenance, initial and recurrent stroke treatment, rehabilitation, long-term care, and caregiver costs. Effectiveness was defined as quality-adjusted life-years (QALYs). Model inputs were obtained from the literature supplemented by data from Georgia Health Sciences University and Mayo Clinic. The base case network included 1 hub and 7 spokes, and assumed no survival benefits from acute treatment in a network. One-way sensitivity analyses were conducted. Compared with no network, patients treated in a telestroke network incurred $1436 lower costs and gained 0.02 QALYs over a lifetime. Incremental costs decreased from $444 for the first year to -$1436 over a lifetime; incremental QALYs increased from 0.002 for the first year to 0.02 over a lifetime. Overall, results were robust in the 1-way sensitivity analyses. A telestroke network became less cost-effective with increasing spoke-to-hub transfer rates. A telestroke network is cost savingand more effective compared with no network from the societal perspective in most modeled scenarios.


  • Open Access

    Cost-Effectiveness of Hub-and-Spoke Telestroke Networks for the Management of Acute Ischemic Stroke From the Hospitals’ Perspectives

    by Jeffrey A. Switzer, Bart M. Demaerschalk, Jipan Xie, Liangyi Fan, Kathleen F. Villa, Eric Q. Wu

    Background—A hub-and-spoke telestroke network is an effective way to extend quality acute stroke care to remote hospitals and to improve patient outcomes. This study assessed the cost-effectiveness of a telestroke network in the management of acute ischemic stroke from the perspectives of a network, a hub hospital, and a spoke hospital. Methods and Results—A model was developed to compare costs and effectiveness with and without a telestroke network over a 5-year time horizon. The model considered differences in rates of teleconsultations, intravenous thrombolysis, endovascular stroke therapies, and spoke-to-hub transfers. These inputs were estimated through the use of data from Georgia Health Sciences University and Mayo Clinic telestroke networks. A network model with 1 hub and 7 spokes predicted that 45 more patients would be treated with intravenous thrombolysis and 20 more with endovascular stroke therapies per year compared with no network, leading to an estimate of 6.11 more home discharges. Each year, a telestroke network was associated with $358 435 in cost savings; each spoke had $109 080 in cost savings, whereas the hub had positive costs of $405 121. However, cost sharing can be arranged so that each hospital could achieve an equal amount of cost savings ($44 804/y). Results were sensitive to the number of spokes, marginal treatment costs in spokes and rates of transfer, and endovascular stroke therapies. Conclusions—The results of this study suggest that a telestroke network may increase the number of patients discharged home and reduce the costs borne by the network hospitals. Hospitals should consider their available resources and the network features when deciding whether to join or set up a network.


  • Minocycline Prevents IL-6 Increase after Acute Ischemic Stroke

    by Jeffrey A. Switzer, Andrea Sikora, Adviye Ergul, Jennifer L. Waller, David C. Hess, Susan C. Fagan

    Higher levels of the inflammatory biomarker interleukin-6 (IL-6) correlate with poor clinical outcome in acute ischemic stroke (AIS). Minocycline (MC) is a known anti-inflammatory agent; thus, the effect of MC on IL-6 in the first 24 h of AIS was investigated to determine potential anti-inflammatory activity. The Minocycline to Improve Neurologic Outcome in Stroke (MINOS) study was a non-randomized dose-escalation (3.0–10.0 mg/kg) trial of IV MC for AIS within 6 h of onset. Plasma IL-6 samples were collected prior to MC treatment at 1, 24, and 72 h and compared to those collected in a separate observational study of blood biomarkers in AIS. IL-6 levels were measured by commercially available ELISA kits. The lower limit of detection for IL-6 was 1 pg/ml. Sixty MINOS subjects and 29 non-MINOS subjects were enrolled, and there was no difference in baseline stroke severity. There was no significant difference in IL-6 level pre-MC treatment at 1, 24, or 72 h. However, the odds of a non-detectable IL-6 at 24 h in MINOS were 8.94 (95% CI 2.62–30.46) compared with non-MINOS subjects. It is likely that even low doses of MC have a potent systemic anti-inflammatory effect in AIS. Whether this results in improved outcome will be tested in a randomized clinical trial.